New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society New preclinical data highlighting potential of CY-101 in ACC and other cancer types driven by a dysfunctional Wnt/β-catenin pathway, including colorectal cancer, to be presented at AACR annual meeting April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its firs

Financing strengthens balance sheet, extending expected runway into the second quarter of 2026 Enables accelerated development of NPM-139, Company’s once or twice-yearly GLP-1 (semaglutide) implant under development for chronic weight management March 27, 2025 -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced that it has entered into a securities purchase agreement

Building the world’s largest biobank with data from global populations to accelerate biomarker and drug discovery and development of next-generation diagnostics. Secured $25M in funding from F-Prime, Helios Digital Ventures, Digitalis Ventures, CEI Ventures, AME Cloud, Alexandria, Founders Collective, Stanford President’s Fund, and HBM Genomics. March 27, 2025 -- Galatea Bio, a leader in AI-driven genomic research and clinical genetic testing has secured $25 million in funding to drive discove

Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical development of lead program ABO-101 and continued advancement of a broader portfolio of CNS-targeted gene editing therapeutics and reverse transcriptase (RT)-based editing programs March 18, 2025 -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines,

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair March 17, 2025 -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines

基于新加坡Hummingbird Bioscience独家授权的多有效载荷抗体-药物偶联技术和项目，Frazier Life Sciences推出Callio Therapeutics 融资由Frazier Life Sciences牵头，Jeito Capital以及包括Novo Holdings A/S、Omega Funds、ClavystBio、Platanus、Norwest、Pureos Bioventures、SEEDS Capital和EDBI在内的其他生命科学投资者大力参与 公司将推进创新的多有效载荷项目，通过克服现有单一有效载荷疗法的局限性，最大限度地提高癌症患者的治疗效果 2025年3月3日 -- 作为一家专注于通过多有效载荷抗体-药物偶联物（ADC）改善癌症治疗的生物技术公司，Callio Therapeutics今日宣布完成1.87亿美元A轮融资并正式启动。 此次融资由Frazier Life Sciences领投，Jeito Capital以及Novo Holdings A/S、Omega Funds、ClavystBio、Platanus、Norwest、

3月3日，丹擎医药 (“Danatlas Pharmaceuticals”）刚刚宣布完成新一轮1.5亿元人民币融资。本轮融资由康君资本领投，阿斯利康中金医疗产业基金、国方创新、磐霖资本等多家知名投资机构跟投，老股东红杉中国持续加注。根据新闻稿，本次融资将用于加速核心管线的临床研究、拓展创新技术平台及全球化战略布局。 丹擎医药自2021年成立以来，搭建了“合成致死”药物研发平台和转化医学平台。其核心产品PARG抑制剂（DAT-2645）已经获得中国NMPA和美国FDA批准开展临床1期研究，该产品正在中国开展临床1期的剂量递增研究，目前展示出良好的安全性、耐受性和抗肿瘤活性。同时，公司有多款创新候选药物研发管线推进至IND阶段。 据丹擎医药此前新闻稿介绍，DAT-2645的适应症包括乳腺癌、卵巢癌、胰腺癌、前列腺癌、子宫癌、胃癌、结直肠癌等多种常见癌症，并且有望拓展PARP抑制剂无效的适应症和解决PARP抑制剂耐药的痛点，具有潜在的“广谱治疗性”的临床应用前景。 除了DAT-2645，丹擎医药官网显示其管线中还包括了其他几款靶向“合成致死”靶点的新药，靶点包括了Polθ、WRN等等。

Specialist fund SCI Ventures, backed by major spinal cord injury foundations, together with existing investors, also participated in this round Proceeds will finance phase 1b/2a study of EG110A through safety and early efficacy results Opens way for clinical development across multiple medically important neuro-urology pathologies Funding will also support the company’s early-stage pipeline based on its proprietary HERMES vector technology platform. February 20, 2025 – EG 427, a biotechnology co

$3.7 Million Private Placement Financing from Existing Investors $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas (CPRIT) Feb. 18, 2025 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company,” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced today that it has closed a private placement with aggregate initial upfront p

Bioxodes raises €2.7 million from existing investors in Series A extension Interim data from BIRCH intracerebral hemorrhage (ICH) Phase 2a trial in Q1 2025 Recruitment of up to 16 additional patients continues in BIRCH BIOX-101 Phase IIb ICH study preparations ongoing, to start upon close of Series B 12 February 2025 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has raised €2.7 millio